Universitatsklinikum Schleswig Holstein Campus

Kiel, Germany

Universitatsklinikum Schleswig Holstein Campus

Kiel, Germany
SEARCH FILTERS
Time filter
Source Type

Dorner L.,Universitatsklinikum Schleswig Holstein Campus | Mustafa A.,Universitatsklinikum Schleswig Holstein Campus | Rohr A.,Universitatsklinikum Schleswig Holstein Campus | Mehdorn H.M.,Universitatsklinikum Schleswig Holstein Campus | Nabavi A.,Universitatsklinikum Schleswig Holstein Campus
Journal of Clinical Neuroscience | Year: 2013

Bis-chloroethylnitrosourea (BCNU; Gliadel, Eisai, Tokyo, Japan) is the only therapeutic agent for local chemotherapy of malignant gliomas approved by the US Food and Drug Administration and the European Medicines Agency. In a small patient cohort, it has previously been shown that glioblastomas recur locally despite treatment with BCNU. This raises concern about local treatment with BCNU as a stand-alone measure. The goal of this study was to analyze the growth pattern of tumor recurrence in a larger patient group: 41 patients were included in this study. Tumor recurrences were morphologically categorized as: local, diffuse, distant or multilocular. Thirty-three of the tumors (80%) that recurred were local or diffuse. These results show that BCNU implantation does not provide lasting local tumor control. Our data support the need to incorporate BCNU in to multimodal therapy schemes. The improved survival rates of patients who receive concomitant local and systemic adjuvant treatment support using local therapy to bridge the therapy-free interval of the initial postoperative phase.


PubMed | Universitatsklinikum Schleswig Holstein Campus
Type: Case Reports | Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia | Year: 2011

Gliadel (Eisai Inc., Woodcliff Lake, NJ, USA) is the only therapeutic agent approved by the Food and Drug Administration and the European Medicines Agency for local chemotherapy of malignant gliomas. With increasing use of this treatment, characteristic side effects have become evident. While most side effects can be managed conservatively, cyst formation requires further intervention. From 2004 to 2009 at our institution 88 patients with malignant gliomas were treated with Gliadel. Ten patients (11%) developed a space-occupying cyst in the resection cavity, seven of which caused clinical symptoms of mass effect that was most prominent 2 weeks after Gliadel implantation (median=16, range=9-30). Despite dexamethasone treatment symptoms progressed, necessitating various surgical interventions. In four patients the cysts were drained percutaneously through a burrhole using a 19-gauge needle. If puncture was not possible (three patients) or not sufficient (two patients), an Ommaya reservoir was implanted for repetitive drainage. In two patients this treatment was combined with open decompression of the cyst. On average, cysts were drained three times. Eventually the symptoms subsided, corresponding to shrinkage of the cysts as shown on follow-up imaging. We describe a serious side effect of local chemotherapy, which may cause rapid clinical deterioration and require direct intervention. While reservoir implantation apparently represents a more elegant treatment option, our experience shows that draining the cyst, even only a few times, sufficiently ameliorates the symptoms and subsequently reverses and halts further cyst enlargement.

Loading Universitatsklinikum Schleswig Holstein Campus collaborators
Loading Universitatsklinikum Schleswig Holstein Campus collaborators